1,720,972 research outputs found
A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia
Full text linkIntroduction: Acute lymphoblastic leukemia is the most frequent hematologic malignancy in children.
Almost 95% of children potentially achieve a complete remission after the induction treatment, but over
the last years, new insights in the genomic disease profile and in minimal residual disease detection
techniques have led to an improvement in the prognostic stratification, identifying selected patients’
subgroups with peculiar therapeutic needs.
Areas covered: According to a comprehensive search of peer-review literature performed in Pubmed, in
this review we summarize the recent evidences on the induction treatment strategies comprised in the
children acute lymphoblastic leukemia scenario, focusing on the role of key drugs such as corticosteroids
and asparaginase and discussing the crucial significance of the genomic characterization at baseline which
may drive the proper induction treatment choice.
Expert opinion: Current induction strategies already produce durable remissions in a significant proportion
of standard-risk children with acute lymphoblastic leukemia. A broader knowledge of the biologic features
related to acute lymphoblastic leukemia subtypes with worse prognosis, and an optimization of targeted
drugs now available, might lead to the achievement of long-term molecular remissions in this setting
Acute myeloid leukemia and ischemic heart disease successful first line treatment with clofarabine as single agent.
No full textMolecular monitoring in core binding factor aml patients undergoing an autologous peripheral blood stem cell transplantation
No full textPOST-REMISSIONAL TREATMENT OF ACUTE MYELOID LEUKAEMIA: COMPLIANCE TO TRANSPLANT PROCEDURES AND LONG-TERM FOLLOW UP
No full text
Follow-up of chronic lymphocytic leukemia (CLL) patients who relapse after autologous stem cell transplantation (ASCT)
No full textHigh dose idarubicine, busulphan e melphalan as conditioning for autilogous blood stem cell transplantation in multiple myeloma. A feasibility study
No full textExtensive studies have tested the clinical impact of double and triple sequential transplants as front-line therapy in MM, following the suggestion that dose escalation can overcome the marked drug resistance characteristic of this disease, but the superiority of such approaches vs one single transplant has still to be demonstrated. The aim of our study was to evaluate the feasibility and efficacy of high-dose idarubicine intensification of a standard busulphan-melphalan conditioning regimen in MM. Twenty-eight patients (median age 55 years) with sensitive disease received PBSCT after high-dose idarubicine combined with busulphan and melphalan and followed by s.c. rhG-CSF until PMN recovery. The most severe toxicity was represented by oral mucositis which resolved with hemopoietic reconstitution. Overall response and CR rate were 52% and 40%, respectively. Currently, 36 patients are alive and 19 are progression-free a median of 20 months (12-36) from transplant. The 3-year projected probability of progression-free survival for patients transplanted after first-line treatment is 60%. The combination of Ida/Bu/Melph appears a promising alternative regimen for PBSCT in myeloma, with low transplant-related toxicity and fast hematological recovery. Long-term follow-up and a prospective randomized study, now ongoing, will probably clarify whether an idarubicine-intensified regimen will result in superior outcomes to conventional conditioning and even be comparable to a double consecutive transplant program
ID-Ara-C, idarubicine and mylotarg gemtuzumab ozogamicin as salvage treatment in advanced AML patients
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
